



Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

April 11, 2023

Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer's disease patients including improvements in measures of cognition and plasma biomarkers

Oral presentation to report new preclinical research supporting the therapeutic potential of enhancement of HGF/MET pathway with fosgonimeton in neurodegenerative conditions

Poster presentation to highlight beneficial effects of ATH-1105 on motor function and survival in an ALS animal model

BOTHELL, Wash., April 11, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced upcoming oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting, which will be held April 22-27, 2023, virtually and at the Boston Convention and Exhibition Center in Boston, Mass. The presentations will highlight additional clinical data from the completed Phase 2 ACT-AD trial of fosgonimeton in people with mild-to-moderate Alzheimer's disease; preclinical data supporting fosgonimeton's mechanism of action and therapeutic potential for neurodegenerative diseases; and preclinical data for ATH-1105 for amyotrophic lateral sclerosis.

AAN 2023 Presentation Details:

Title: [Therapeutic Potential of Fosgonimeton, a Small-Molecule Positive Modulator of the Neurotrophic HGF/MET Pathway, in Neurodegenerative Conditions](#)

Format: Oral (abstract #3944, presentation #008)

Session: S14: General Neurology: Emerging Therapies

Presenter: Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma

Date/Time: Monday, April 24, at 2:24 p.m. EDT

Title: [Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating with Composite Clinical Score of Cognition and Function in Alzheimer's Disease](#)

Format: Oral (abstract #4214, presentation #008)

Session: S26: Experimental Therapeutics in Dementia

Presenter: Hans J. Moebius, M.D., Ph.D., Chief Medical Officer, Athira Pharma

Date/Time: Tuesday, April 25, at 2:24 p.m. EDT

Title: [Small Molecule Positive Modulator of Hepatocyte Growth Factor \(HGF\)/MET, ATH-1105, Improves Function and Reduces Disease Biomarkers in a TDP-43 Mouse Model of Amyotrophic Lateral Sclerosis](#)

Format: Poster (abstract #3277)

Session: P8: Neuromuscular Disease: Amyotrophic Lateral Sclerosis 1

Presenter: Jewel Johnston, Ph.D., Director, In Vivo Pharmacology, Athira Pharma

Date/Time: Tuesday, April 25, from 11:45 a.m. - 12:45 p.m. EDT

All presentations will be available on the [Scientific Publications & Presentations](#) page of the company's website at www.athira.com.

About Athira Pharma, Inc.

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer's and Parkinson's disease, Dementia with Lewy bodies and amyotrophic lateral sclerosis (ALS). For more information, visit www.athira.com. You can also follow Athira on [Facebook](#), [LinkedIn](#), and @athirapharma on [Twitter](#) and [Instagram](#).

Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for Alzheimer's disease, Parkinson's disease dementia, Dementia with Lewy bodies, and other neurodegenerative diseases, such as amyotrophic lateral sclerosis; Athira's platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof; expectations regarding the potential efficacy and commercial potential of Athira's product candidates; and Athira's ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "on track," "would," "expect," "plan," "believe," "intend," "pursue," "continue," "suggest," "potential," and other similar expressions, among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data for our product candidates from our preclinical and clinical trials not supporting the safety, efficacy and tolerability of our product candidates; cessation or delay of Athira's development of product candidates may occur; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval;

the impact of the COVID-19 pandemic on Athira's business, research and clinical development plans and timelines, and the regulatory process for Athira product candidates; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against us and certain of our directors and officers; clinical trials may not demonstrate safety and efficacy of any of Athira's product candidates; possible negative interactions of Athira's product candidates with other treatments; Athira's assumptions regarding the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira's clinical development plans as a result of the COVID-19 pandemic, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Investor & Media Contact

Julie Rathbun

Athira Pharma

Julie.rathbun@athira.com

206-769-9219